Evidence
Am J Addict. 2023 Dec 9. doi: 10.1111/ajad.13505. Online ahead of print.
ABSTRACT
BACKGROUND AND OBJECTIVES: In April 2021, the Department of Health and Human Services released new federal practice guidelines and allowed physicians who wish to treat ≤30 patients with opioid use disorder (OUD) to forego the X-waiver training requirement.
METHODS: This observational study compared annual number, dose, and spending of buprenorphine OUD treatments dispensed in the Medicaid population in 2021 versus 2020 using the CMS State Drug Utilization Data (n = 50 states plus D.C.).
RESULTS: Compared to 2020, there was a slight decrease (-3.1%) in the annual number of buprenorphine prescriptions dispensed but an increase in total doses (+3.2%) and payment (10.6%) for buprenorphine prescriptions in 2021.
DISCUSSION AND CONCLUSIONS: Decrease in number of buprenorphine prescriptions in Medicaid population was observed in 2021.
SCIENTIFIC SIGNIFICANCE: Our findings support the hypothesis generation in which the removal of X-waiver training alone is not adequate to increase prescribing and access to OUD treatment buprenorphine.
PMID:38069608 | DOI:10.1111/ajad.13505
Add to Google Keep
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D
Real-Time Evidence Search [Psychiatry]
AI Search [Komo.ai]
Did the 2021 federal change in the practice guidelines for the administration of buprenorphine for treating opioid use disorder increase buprenorphine prescription dispensing in Medicaid population?
🌐 90 Days
VR Related Evidence Matrix
- Emergency Department Access to Buprenorphine for Opioid Use Disorder
- Buprenorphine misinformation and willingness to treat patients with opioid use disorder among primary care-aligned health care professionals
- Cognitive processing therapy (CPT) versus individual drug counseling (IDC) for PTSD for veterans with opioid use disorder maintained on buprenorphine
- Prescribing practices in opioid agonist treatment and changes in compliance to clinical dosing guidelines in British Columbia, Canada
- Characterizing Acute and Postsurgical Pain Management in Patients Receiving Buprenorphine or Buprenorphine/naloxone
- Prescription opioid dispensing patterns among patients with schizophrenia or bipolar disorder
- Buprenorphine: two adolescent case reports of bridging the transmucosal form to the extended-release subcutaneous injectable form
- Higher First 30-Day Dose of Buprenorphine for Opioid Use Disorder Treatment Is Associated With Decreased Mortality
- Impact of the Communities That HEAL Intervention on Buprenorphine-Waivered Practitioners and Buprenorphine Prescribing: A Prespecified Secondary Analysis of the HCS Randomized Clinical Trial
- A population-based time-series analysis of opioid agonist treatment dispensed during pregnancy
- First Trimester Use of Buprenorphine or Methadone and the Risk of Congenital Malformations
- Medication-based treatment among rural, primary care patients diagnosed with opioid use disorder and alcohol use disorder
- Comparative Analysis of Instrumental Variables on the Assignment of Buprenorphine/Naloxone or Methadone for the Treatment of Opioid Use Disorder
- Stepped Care for Patients to Optimize Whole Recovery (SC-POWR): An Effectiveness Trial Evaluating a Stepped Care Model for Individuals With Opioid Use Disorder and Chronic Pain
- It takes a village: A pilot study of a group telehealth intervention for support persons affected by opioid use disorder
- Analysis of nonfatal suicide attempts and demographic characteristics of US military veterans with opioid use disorder: A descriptive VA medical center study
- High Interest in Injectable Opioid Agonist Treatment With Hydromorphone Among Urban Syringe Service Program Participants
- Opioids in geriatric units in 14 Belgian hospitals: prevalence, dosage and associated factors
- Multimodal Acute Pain Management in the Parturient with Opioid Use Disorder: A Review
- Dialing for doctors: Secret shopper study of Arizona methadone and buprenorphine providers, 2022
- Withdrawal during outpatient low dose buprenorphine initiation in people who use fentanyl: a retrospective cohort study
- Trends in maternal opioid use disorder and neonatal abstinence syndrome in Maine, 2016-2022
- Unintended consequences of methadone regulation for opioid use disorder treatment among hospitalized patients
- Withdrawal catastrophizing scale: initial psychometric properties and implications for the study of opioid use disorder and hyperkatifeia
- Medications for opioid use disorder associated with reduced readmissions for patients with severe injection-related infections: A matched cohort study
- Building bridges to outpatient treatment services for post-overdose care via paramedic buprenorphine field initiation
- Building bridges to outpatient treatment services for post-overdose care via paramedic buprenorphine field initiation
- Opioid-induced hypogonadism in opioid use disorder, its role in negative reinforcement, and implications for treatment and retention
- An Australian retrospective observational cohort comparison of the use of long-acting injectable buprenorphine products
- Declining but Pronounced State-Level Disparities in Prescription Opioid Distribution in the United States
- The impact of changes in opioid dependency treatment upon COVID-19 transmission in Sydney, Australia: a retrospective longitudinal observational study
- Emerging Trends in Opioid Use Disorder Management: A 6-Year Analysis of Emergency Department Visits, Buprenorphine Prescriptions, and Naloxone Distribution (2016-2021)
- Extended-release buprenorphine in pregnancy
- Association of copayments with healthcare utilization and expenditures among medicaid enrollees with a substance use disorder
- Referral of patients from rural primary care clinics to telemedicine vendors for opioid use disorder treatment: A mixed-methods study
- Social Determinants of Health and Continuity of Medications for Opioid Use Disorder Among Patients Receiving Treatment in Rural Primary Care Settings
- Trend of using cementless total knee arthroplasty: a nationwide analysis from 2015 to 2021
- Two-year Opioid Prescription Trends in Local Sanitary Agency Naples 3 South, Campania Region, Italy. Descriptive Analyses and AI-based Translational Perspectives
- Prescribing and Acceptance of Medications for Opioid Use Disorder in VA Primary Care: Veteran and Provider Perspectives
- Target trial emulation for comparative effectiveness research with observational data: Promise and challenges for studying medications for opioid use disorder
- 10-year retention of a comprehensive treatment model of buprenorphine for opioid use disorder
- Diffusion of medications for opioid use disorder treatment in jail settings: a convergent mixed methods study of jail staff perspectives
- The lived experiences and treatment needs of women with opioid use disorder and posttraumatic stress symptoms: A mixed methods study of women and providers
- Assessing men with opioid use disorder for testosterone deficiency after the development of symptoms
- Outcomes of an Interprofessional Opioid Training Program for Graduate Students in Nursing and Social Work
- Timing of treatment for opioid use disorder among birthing people
- Regional differences in fatal drug overdose deaths among Black and White individuals in the United States, 2012-2021
- The association of pain impact and sleep disruption with opioid withdrawal during opioid-use disorder treatment
- Diagnosis of Perinatal Mental Health Conditions Following Medicaid Expansion to Include Low-Income Immigrants
- Pediatric Primary Care Clinicians' Perspectives on Telemedicine Use, 2020 Versus 2021
- Patterns of psychotropic drug prescriptions and general practice consultations among community-dwelling older people with dementia during the first two years of the COVID-19 pandemic
- Tools to implement measurement-based care (MBC) in the treatment of opioid use disorder (OUD): toward a consensus
- Application of an opioid use disorder cascade of care in a large public health system
- Drug utilisation in children and adolescents before and after the start of the COVID-19 pandemic: Interrupted time-series analyses in three European countries
- Opioid versus Benzodiazepine-based Sedation for Mechanically Ventilated Patients in the Internal Medicine Ward
- Off-label prescribing of psychotropics in a psychiatric patient population in Australia
- Association of state-level prescription drug monitoring program implementation with opioid prescribing transitions in primary care in Australia
- Availability of substance use disorder treatment in Spanish: Associations with state-level proportions of Spanish speakers and treatment facility characteristics in the United States
- Processing abnormalities in monetary outcome evaluations among male individuals with opioid use disorder: evidence from feedback-related negativity
- Who Provides Outpatient Clinical Care for Adults With ADHD? Analysis of Healthcare Claims by Types of Providers Among Private Insurance and Medicaid Enrollees, 2021
- Characteristics of Opioid Toxicity Deaths Among Adolescents and Young Adults in Ontario Prior To and During the COVID-19 Pandemic
- Cognitive behavioral therapy for anxiety and opioid use disorder: Development and pilot testing
- "Naloxone? Not for me!" First cross-assessment by patients and healthcare professionals of the risk of opioid overdose
- Emergency Room Utilization and Methamphetamine Overdose Symptoms Among Syringe Services Program Participants in Washington State
Evidence Blueprint
Did the 2021 federal change in the practice guidelines for the administration of buprenorphine for treating opioid use disorder increase buprenorphine prescription dispensing in Medicaid population?
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
Save Evidence Blueprint
Save as PDF
Did the 2021 federal change in the practice guidelines for the administration of buprenorphine for treating opioid use disorder increase buprenorphine prescription dispensing in Medicaid population?
🌐 365 Days
VR Related Evidence Matrix
- Removal of Medicaid Prior Authorization Requirements and Buprenorphine Treatment for Opioid Use Disorder
- Buprenorphine and Opioid Use Disorder Training: Graduate Nursing Curricula Recommendations
- Change in opioid and buprenorphine prescribers and prescriptions by specialty, 2016-2021
- Characteristics and Prescribing Patterns of Clinicians Waivered to Prescribe Buprenorphine for Opioid Use Disorder Before and After Release of New Practice Guidelines
- Association of Selected State Policies and Requirements for Buprenorphine Treatment With Per Capita Months of Treatment
- State alignment with federal regulations in 2022 to relax buprenorphine 30-patient waiver requirements
- An analysis of patterns of distribution of buprenorphine in the United States using ARCOS, Medicaid, and Medicare databases
- Urine drug testing among Medicaid enrollees initiating buprenorphine treatment for opioid use disorder within 9 MODRN states
- Pain Management in Patients With Opioid Use Disorder on Extended-release Buprenorphine: A Case Report
- The End of the X-waiver: Excitement, Apprehension, and Opportunity
- ASAM Clinical Considerations: Buprenorphine Treatment of Opioid Use Disorder for Individuals Using High-potency Synthetic Opioids
- Emergency Department Access to Buprenorphine for Opioid Use Disorder
- Racial and Ethnic Inequities in Buprenorphine and Methadone Utilization Among Reproductive-Age Women with Opioid Use Disorder: an Analysis of Multi-state Medicaid Claims in the USA
- Initiation of Extended-release Depot Buprenorphine in a Patient Subject to a Community Treatment Order for Both Antipsychotic and Opioid Agonist Treatments
- Buprenorphine misinformation and willingness to treat patients with opioid use disorder among primary care-aligned health care professionals
- National Trends in Buprenorphine Treatment for Opioid Use Disorder From 2007 to 2018
- Doing Our Best in a Broken System: The Urgent Need for Expansion of Medication for Opioid Use Disorder Treatments in the United States
- Missed Opportunities: Substance Use Hotline Operator Uncertainty of State Buprenorphine Prescribing via Telemedicine
- Exploring the Association of State Policies and the Trajectories of Buprenorphine Prescriber Patient Caseloads
- Buprenorphine use and setting type among reproductive-aged women self-reporting nonmedical prescription opioid use
- Buprenorphine and opioid analgesics: Dispensation and discontinuity among accidental overdose fatalities in the Indianapolis metropolitan area, 2016-2021
- Changes in Opioid Agonist Treatment Practice in Germany during the COVID-19 Pandemic: What Have Physicians Done, and What Would They Like to Keep Doing?
- The association of medical providers' attitudes about naloxone and people with opioid use disorder and their self-reported "low-barrier" treatment practices
- Treatment of poppy seed tea misuse with buprenorphine in a telehealth practice: a case series
- Prescriptions for Buprenorphine in Michigan Following an Education Intervention
- Cognitive processing therapy (CPT) versus individual drug counseling (IDC) for PTSD for veterans with opioid use disorder maintained on buprenorphine
- Perspectives on and experiences of emergency department-initiated buprenorphine among clinical pharmacists: A multi-site qualitative study
- Extended-release Buprenorphine Administered at Discharge in Hospitalized Persons With Opioid Use Disorder: A Case Series
- Patient opinion and acceptance of emergency department buprenorphine/naloxone to-go home initiation packs
- Buprenorphine deregulation as an opioid crisis policy response - A comparative analysis between France and the United States
- Evidence on Buprenorphine Dose Limits: A Review
- Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder
- Low-Dose Initiation of Buprenorphine: A Narrative Review
- Pharmacokinetic-pharmacodynamic analysis of drug liking blockade by buprenorphine subcutaneous depot (CAM2038) in participants with opioid use disorder
- An Appraisal of Using Opioids in Patients with Opioid Use Disorder
- Associations of methadone and buprenorphine-naloxone doses with unregulated opioid use, treatment retention, and adverse events in prescription-type opioid use disorders: Exploratory analyses of the OPTIMA study
- Opioid use disorder treatment and the role of New Jersey Medicaid policy changes: perspectives of office-based buprenorphine providers
- Measuring time in buprenorphine treatment stages among people with HIV and opioid use disorder by retention definition and its association with cocaine and hazardous alcohol use
- Buprenorphine adherence and illicit opioid use among patients in treatment for opioid use disorder
- Kratom use disorder: case reports on successful treatment with home induction of buprenorphine-naloxone
- Prescribing practices in opioid agonist treatment and changes in compliance to clinical dosing guidelines in British Columbia, Canada
- Acute Pain Management for Patients Maintained on Sublingual Buprenorphine as Medication for Opioid Use Disorder
- Characterizing Acute and Postsurgical Pain Management in Patients Receiving Buprenorphine or Buprenorphine/naloxone
- Trends in Incident Prescriptions for Behavioral Health Medications in the US, 2018-2022
- Expanding access to Medication for Opioid Use Disorder (MOUD) in jails: A comprehensive program evaluation
- Association of MOUD ECHO Participation on Expansion of Buprenorphine Prescribing in Rural Primary Care
- Treating opioid use disorder in veterans with co-occurring substance use: a qualitative study with buprenorphine providers in primary care, mental health, and pain settings
- Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder
- Prescription opioid dispensing patterns among patients with schizophrenia or bipolar disorder
- Medical and genetic correlates of long-term buprenorphine treatment in the electronic health records
- The Perceived Role of Withdrawal in Maintaining Opioid Addiction among Adults with Untreated Opioid Use Disorder: A Survey of Syringe Exchange Program Participants
- Survey of barriers and opportunities for prescribing buprenorphine for opioid use disorder in Alabama
- Hospital-based opioid treatment: Expanding and sustaining the model in Texas
- Gabapentin Use Among Individuals Initiating Buprenorphine Treatment for Opioid Use Disorder
- Buprenorphine: two adolescent case reports of bridging the transmucosal form to the extended-release subcutaneous injectable form
- Unfilled prescriptions: Surveying patients' experiences with buprenorphine treatment in Massachusetts before and during the COVID-19 pandemic
- Higher First 30-Day Dose of Buprenorphine for Opioid Use Disorder Treatment Is Associated With Decreased Mortality
- Health care use and cost of treatment for adolescents and young adults with opioid use disorder
- Impact of the Communities That HEAL Intervention on Buprenorphine-Waivered Practitioners and Buprenorphine Prescribing: A Prespecified Secondary Analysis of the HCS Randomized Clinical Trial
- Non-overdose acute care hospitalizations for opioid use disorder among commercially-insured adults: a retrospective cohort study
- Risks of opioid overdose among New York State Medicaid recipients with chronic pain before and during the COVID-19 pandemic
- The impact of the implementation of medication for opioid use disorder and COVID-19 in a statewide correctional system on treatment engagement, postrelease continuation of care, and overdose
- A population-based time-series analysis of opioid agonist treatment dispensed during pregnancy
- Medications for opioid use disorder: An interactive educational program developed for the nurse practitioner curriculum